Resolvyx Initiates Clinical Trial Of RX-10001

Resolvyx has initiated the first human phase-I clinical trial, evaluating an oral resolvin therapeutic, RX-10001 in healthy volunteers.

RX-10001 is a synthetic form of RvE1, a naturally occurring resolvin, for inflammation and to promote healing for normal tissue function.

The randomized, placebo-controlled, double-blind study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RX-10001.

In addition, 56 healthy volunteers will be enrolled in the trial which will evaluate a single as well as a multiple ascending dose of RX-10001, to be administered orally.

Per Gjorstrup, CMO of Resolvyx, said: “Based on its unique mechanism of action and compelling preclinical data, we are hopeful that RX-10001 will offer a novel therapeutic approach for a broad number of inflammatory diseases, beginning with asthma.”